Review evaluates IL-32's role as a biomarker and therapeutic target in cardiovascular diseases, suggesting new treatment avenues.
Cardiovascular diseases remain a leading cause of death worldwide, driven by complex pathological mechanisms involving various cytokines and inflammatory responses. IL-32, a recently discovered cytokine, has emerged as a key player in the pathogenesis of cardiovascular diseases, including atherosclerosis, myocardial infarction, and heart failure. This review summarizes the biological characteristics of IL-32 and its role in cardiovascular diseases, explores its involvement in inflammatory responses and other pathological processes, and evaluates its potential as both a biomarker and a therapeutic target. Collectively, this review aims to provide new insights for the prevention and treatment of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: